A case of coagulation factor V inhibitor induced by immune checkpoint inhibitor therapy

A 73-year-old woman with lung adenocarcinoma (cT4N3M1a: Stage IVA) was treated with atezolizumab as the eighth line of therapy. Four weeks after the fourth dose of atezolizumab, the prothrombin time (PT) and activated thromboplastin time (APTT) were prolonged. Coagulation factor V (FV) activity was...

Full description

Saved in:
Bibliographic Details
Published in:Respirology case reports 2024, Vol.12 (2), p.e01307-e01307
Main Authors: Haruta, Yuki, Azuma, Masanori, Sado, Toshikatsu, Saito, Ryuichi, Miyazaki, Yoshimune, Noda, Akihiro, Kitagawa, Reina, Hori, Yasutaka, Fujimoto, Sayaka, Hasegawa, Yoshinori, Ueda, Tetsuya, Yamamura, Ryosuke
Format: Report
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A 73-year-old woman with lung adenocarcinoma (cT4N3M1a: Stage IVA) was treated with atezolizumab as the eighth line of therapy. Four weeks after the fourth dose of atezolizumab, the prothrombin time (PT) and activated thromboplastin time (APTT) were prolonged. Coagulation factor V (FV) activity was decreased, and FV inhibitors were observed. There was no history of PT or APTT prolongation or bleeding before the use of atezolizumab. Atezolizumab-induced coagulation FV inhibitor was diagnosed. After 2 weeks, the PT and APTT spontaneously normalized. FV activity improved and the FV inhibitors disappeared after 6 and 9 weeks, respectively.
ISSN:2051-3380
2051-3380
DOI:10.1002/rcr2.1307